Comment on Wang et al. Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer’s Disease. Int. J. Mol. Sci. 2023, 24, 13927
Open Access
- 11 March 2025
- journal article
- editorial
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2480
Abstract
The authors have published their findings that simufilam, a small novel molecule suggested for clinical use in Alzheimer’s disease (AD), restores a deleterious conformation of filamin A (FLNA), which is a large intracellular scaffolding protein, as indicated by changes in isoelectric focusing pointsKeywords
This publication has 19 references indexed in Scilit:
- A model of lipid dysregulation and altered nutrient status in Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2019
- Tau Protein Levels in ADHDIndian Journal of Clinical Biochemistry, 2018
- Exposure to nitrous oxide and intrusive memory formation in psychological traumaPsychological Medicine, 2018
- ADHD and comorbid migraineEpilepsy & Behavior, 2018
- Antecedent ADHD, dementia, and metabolic dysregulation: A U.S. based cohort analysisNeurochemistry International, 2018
- Use of anthropogenic nitrogen fertilizers in agriculture is associated with per capita ethanol consumptionMedical Hypotheses, 2017
- Exposure to ambient PM10 and nitrogen dioxide and ADHD risk: A reply to Min & Min (2017)Environment International, 2017
- Does environmental exposure to the greenhouse gas, N 2 O, contribute to etiological factors in neurodevelopmental disorders? A mini-review of the evidenceEnvironmental Toxicology and Pharmacology, 2016
- Does MeCP2 deficiency in autism confer protection against later development of Alzheimer’s disease? A reply to Oberman and Pascual-Leone (2014)Medical Hypotheses, 2016
- The stimulation of central κ opioid receptors decreases male sexual behavior and locomotor activityBrain Research, 1992